Blog
RSS FeedPosted by Michael Wonder on 23 Apr 2018
Cost-effectiveness thresholds: the past, the present and the future
23 April 2018 - Cost-effectiveness (CE) thresholds are being discussed more frequently and there have been many new developments in this ...
Posted by Michael Wonder on 13 Apr 2018
Decision components of NICE's technology appraisals assessment framework
10 April 2018 - The UK's NICE is an established health technology assessment agency. de Folter et al. present a ...
Posted by Michael Wonder on 28 Mar 2018
In battle to cut drug prices, outcome-based pricing carries big risks for biopharma
28 March 2018 - In a provocative piece entitled “Trump’s Health Secretary Wants To Transform Healthcare. Can He?”, fellow Forbes contributor, ...
Posted by Michael Wonder on 22 Mar 2018
Resolving the “cost-effective but unaffordable” paradox: estimating the health opportunity costs of non-marginal budget impacts
22 March 2018 - Considering whether or not a proposed investment (an intervention, technology, or program of care) is affordable is ...
Posted by Michael Wonder on 18 Mar 2018
Policy strategies for aligning price and value for brand-name pharmaceuticals
15 March 2018 - Systemic factors in the US health care system lead to greater pricing power for drug manufacturers than ...
Posted by Michael Wonder on 06 Mar 2018
UnitedHealth Group hits $64 billion in value based care spending
5 March 2018 - UnitedHealth Group, the nation’s largest health insurance company, says it’s paying nearly 60% of its reimbursements ...
Posted by Michael Wonder on 22 Feb 2018
A health economics approach to US value frameworks: serving the needs of decision-making
22 February 2018 - Value assessment is an integral component of decision making in health and is the focus of a ...
Posted by Michael Wonder on 20 Feb 2018
Beyond QALYs: multi-criteria based estimation of maximum willingness to pay for health technologies
20 February 2018 - The QALY is a useful outcome measure in cost-effectiveness analysis. But in determining the overall value of ...
Posted by Michael Wonder on 28 Jan 2018
Is “end of life” a special case? Connecting Q with survey methods to measure societal support for views on the value of life-extending treatments
19 January 2018 - Preference elicitation studies reporting societal views on the relative value of end-of-life treatments have produced equivocal results. ...
Posted by Michael Wonder on 25 Jan 2018
Value based pricing: l'enfant terrible?
25 January 2018 - Concern over pricing of pharmaceuticals and other health technologies in both high- and low-income countries is not ...
Posted by Michael Wonder on 24 Jan 2018
How excluding some benefits from value assessment of new drugs impacts innovation
23 January 2018 - Payers often assess the benefits of new drugs relative to costs for reimbursement purposes, but they frequently ...
Posted by Michael Wonder on 23 Jan 2018
Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
23 January 2018 - Although health technology assessment systems base their decision making process either on economic evaluations or comparative clinical ...
Posted by Michael Wonder on 13 Jan 2018
Estimating the reference incremental cost-effectiveness ratio for the Australian health system
22 December 2017 - The objective of this study was to estimate the expected incremental cost per quality-adjusted life-year (QALY) ...
Posted by Michael Wonder on 06 Jan 2018
Association of immunotherapy with durable survival as defined by value frameworks for cancer care
28 December 2017 - Modern immuno-oncology agents have generated great excitement because of their potential to provide durable survival for some ...
Posted by Michael Wonder on 29 Dec 2017
Estimating a cost-effectiveness threshold for the Spanish NHS
28 December 2017 - The cost of generating a quality-adjusted life year within a National Health Service provides an approximation of ...